All In Biotech

Drug Trial Radar · NCT02882984

Hypofractionated Brain Radiation In EGFR Mutated Adenocarcinoma Cranial Disease (Hybrid)

Comparing Whole Brain Radiation With Hypofractionated Stereotactic RadioSurgery (HFSRS) in Patients With NSCL Brain Metastases

Last checked: Nov 19, 2026Latest source record: Aug 30, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 325 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

325

Planned (sponsor's estimate)

Start

Mar 2015

Primary completion

Mar 2020

Study completion Dec 2020

Sponsor

Lead sponsor
Sichuan Provincial People's HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 30, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 99 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multi-center phase III randomized controlled study to evaluate the efficacy of Hypofractionated SRS (HFSRS) along with EGFR-TKI in patients with brain metastasis from non-small cell lung cancer (NSCLC). Assuming that HFSRS is not inferior to EGFR-TKI concurrent with whole brain radiotherapy (WBRT), the primary end point is intracranial PFS (iPFS), while secondary outcomes included overall survival (OS), evaluation of cognitive function, quality of life (QoL) and adverse events.

Conditions

  • Stage IV EGFR Mutated NSCL With Brain Metastases

Interventions

  • Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/IcotinibDrug

    radiation given along with one of kind TKI

  • WBRTRadiation

    3750 cGy in 15 fractions given within 3 weeks time.

  • HFSRSRadiation

    All HFSRS given in 5 fractions. dose per fraction ranges from 5 to 8 Gy depending on the target volume and organs at risk tolerance.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. iPFSTime frame: 18 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Sichuan PPH, Cancer Center

    Chengdu, Sichuan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.